-
1
المؤلفون: Daniela Rojo, Anna Badner, Louisa Dal Cengio, Samuel Kim, Noriaki Sakai, Jacob Greene, Ella Eisinger, Caroline Arellano-Garcia, Lindsey C. Mehl, Mohammad E. Gumma, Rebecca L. Soyk, Julia Ransom, Maya K. Weigel, Belgin Yalçın, Samuel E. Jones, Hanna M. Ollila, Seiji Nishino, Erin M. Gibson
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::82829a9b2ea84c44e58212572c0ba3cb
https://doi.org/10.1101/2022.04.28.489946 -
2
المؤلفون: Ella Eisinger, Siyu Shi, Reena Thomas, Joseph Abi Jaoube, Ruhi Kanwar, Justin M. Moore, Vamsi Varanasi, Alvaro Amorin, Michael C. Jin
المصدر: Journal of neuro-oncology. 148(2)
مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Neurology, Adolescent, medicine.medical_treatment, Pembrolizumab, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Antineoplastic Agents, Immunological, Internal medicine, Neoplasms, medicine, Humans, Adverse effect, Child, Immune Checkpoint Inhibitors, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Melanoma, Retrospective cohort study, Immunotherapy, Middle Aged, medicine.disease, Discontinuation, Nivolumab, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Female, Neurology (clinical), Nervous System Diseases, business, 030217 neurology & neurosurgery